Skip to main content
. 2015 Sep 2;132(18):1719–1725. doi: 10.1161/CIRCULATIONAHA.115.017119

Figure 2.

Figure 2.

Effect of ivabradine on Vo2 peak in the heart failure with preserved ejection fraction (HFpEF) cohort. Depicts the change in Vo2 peak (mL·kg−1·min−1) with placebo (left) and ivabradine (right; ivabradine vs placebo, P=0.003) in the HFpEF cohort.